How are you using circulating tumor DNA in your clinical decisions for HPV-associated OPSCC?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on
We have a post-operative trial where we are using cfDNA as an integral marker to decide on adjuvant therapy for HPV+ OPC.
Join for free or sign in to see the full answer